| 1 |
32401663 |
10.1080/15513815.2020.1764680 |
2022 |
PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance? |
CD274 |
| 2 |
33722840 |
10.1136/jclinpath-2020-207280 |
2022 |
Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP). |
CD274 |
| 3 |
33870634 |
10.1111/ajco.13549 |
2022 |
Suitability of endobronchial ultrasound-guided transbronchial needle aspiration samples for programmed death ligand-1 testing in non-small cell lung cancer, the Bristol experience. |
CD274 |
| 4 |
34520052 |
10.1111/bjh.17793 |
2022 |
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. |
CD274 |
| 5 |
34585994 |
10.1080/10428194.2021.1984454 |
2022 |
Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia. |
CD274 |
| 6 |
34841687 |
10.1111/1759-7714.14216 |
2022 |
Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. |
CD274 |
| 7 |
34842351 |
10.1002/cam4.4462 |
2022 |
PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders. |
CD274 |
| 8 |
34862664 |
10.1111/apm.13195 |
2022 |
Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population. |
CD274 |
| 9 |
34903527 |
10.1101/gr.275911.121 |
2022 |
Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers. |
CD274 |
| 10 |
34936940 |
10.1016/j.ejca.2021.11.013 |
2022 |
Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. |
CD274 |
| 11 |
34959071 |
10.1016/j.molimm.2021.12.014 |
2022 |
HomA and HomB, outer membrane proteins of Helicobacter pylori down-regulate activation-induced cytidine deaminase (AID) and Ig switch germline transcription and thereby affect class switch recombination (CSR) of Ig genes in human B-cells. |
CD274 |
| 12 |
34968160 |
10.1080/21655979.2021.2014617 |
2022 |
microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1. |
CD274 |
| 13 |
34996890 |
10.1038/s41598-021-02515-5 |
2022 |
The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma. |
CD274 |
| 14 |
35032188 |
10.1007/s00277-022-04760-8 |
2022 |
Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma. |
CD274 |
| 15 |
35165282 |
10.1038/s41467-022-28479-2 |
2022 |
EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. |
CD274 |
| 16 |
35194801 |
10.1111/bjd.21063 |
2022 |
Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome. |
CD274 |
| 17 |
35344582 |
10.1182/blood.2021014007 |
2022 |
Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies. |
CD274 |
| 18 |
35359004 |
10.1182/bloodadvances.2022007104 |
2022 |
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. |
CD274 |
| 19 |
35373781 |
10.23736/S2784-8671.22.07275-9 |
2022 |
PD-1 and PD-L1 expression in mycosis fungoides and Sézary Syndrome. |
CD274 |
| 20 |
35417939 |
10.3324/haematol.2021.280352 |
2022 |
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. |
CD274 |
| 21 |
35443604 |
10.7754/Clin.Lab.2021.210701 |
2022 |
Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia. |
CD274 |
| 22 |
35644823 |
10.1186/s43046-022-00121-8 |
2022 |
The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt. |
CD274 |
| 23 |
35655072 |
10.1038/s41598-022-13101-8 |
2022 |
Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL. |
CD274 |
| 24 |
35680804 |
10.19746/j.cnki.issn.1009-2137.2022.03.018 |
2022 |
[Inhibitory Effect of Interference with PD-L1 Expression on B-cell lymphoma in Mice]. |
CD274 |
| 25 |
35741318 |
10.3390/diagnostics12061507 |
2022 |
Hodgkin Lymphoma: Biology and Differential Diagnostic Problem. |
CD274 |
| 26 |
35764886 |
10.1038/s41598-022-15162-1 |
2022 |
Mutations in the miR-142 gene are not common in myeloproliferative neoplasms. |
CD274 |
| 27 |
35767735 |
10.1182/bloodadvances.2022007046 |
2022 |
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade. |
CD274 |
| 28 |
35774848 |
10.1155/2022/3276925 |
2022 |
Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. |
CD274 |
| 29 |
35789115 |
10.1111/his.14718 |
2022 |
Hodgkinoid histiocytosis: an atypical nodal CD30 and S100-positive histiocytosis with eosinophilia. |
CD274 |
| 30 |
35848760 |
10.1097/PAS.0000000000001899 |
2022 |
9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions. |
CD274 |
| 31 |
35922773 |
10.1186/s12885-022-09803-x |
2022 |
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma. |
CD274 |
| 32 |
31608729 |
10.1080/10428194.2019.1675880 |
2021 |
PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. |
CD274 |
| 33 |
32803453 |
10.1007/s00428-020-02901-w |
2021 |
Clinicopathological analysis of neoplastic PD-L1-positive EBV<sup>+</sup> diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort. |
CD274 |
| 34 |
32815748 |
10.1080/0284186X.2020.1806358 |
2021 |
Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014. |
CD274 |
| 35 |
32871584 |
10.1182/blood.2020006464 |
2021 |
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. |
CD274 |
| 36 |
32964767 |
10.1080/10428194.2020.1821011 |
2021 |
Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. |
CD274 |
| 37 |
33028589 |
10.1158/1078-0432.CCR-20-1457 |
2021 |
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. |
CD274 |
| 38 |
33091534 |
10.1016/j.canlet.2020.10.024 |
2021 |
NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma. |
CD274 |
| 39 |
33184699 |
10.1007/s00262-020-02787-2 |
2021 |
Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma. |
CD274 |
| 40 |
33196892 |
10.1007/s00432-020-03444-y |
2021 |
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China. |
CD274 |
| 41 |
33232972 |
10.1182/blood.2020005244 |
2021 |
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. |
CD274 |
| 42 |
33247999 |
10.1111/cas.14752 |
2021 |
Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer. |
CD274 |
| 43 |
33277223 |
10.1016/j.clml.2020.11.009 |
2021 |
Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. |
CD274 |
| 44 |
33299141 |
10.1038/s41375-020-01105-0 |
2021 |
Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression. |
CD274 |
| 45 |
33369766 |
10.1002/hon.2836 |
2021 |
Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement. |
CD274 |
| 46 |
33389078 |
10.1007/s00432-020-03446-w |
2021 |
Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma. |
CD274 |
| 47 |
33454550 |
10.1016/j.ejmech.2021.113170 |
2021 |
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. |
CD274 |
| 48 |
33480087 |
10.1002/hon.2839 |
2021 |
High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup. |
CD274 |
| 49 |
33512416 |
10.1182/blood.2020007245 |
2021 |
Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. |
CD274 |
| 50 |
33517324 |
10.2967/jnumed.120.258384 |
2021 |
Synthesis and Preclinical Evaluation of a <sup>68</sup>Ga-Labeled Adnectin, <sup>68</sup>Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression. |
CD274 |
| 51 |
33558066 |
10.1016/j.pathol.2020.11.004 |
2021 |
CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients. |
CD274 |
| 52 |
33560388 |
10.1182/bloodadvances.2020002371 |
2021 |
Pembrolizumab in mycosis fungoides with PD-L1 structural variants. |
CD274 |
| 53 |
33590326 |
10.1007/s00595-021-02236-2 |
2021 |
Immunotherapeutic advances in gastric cancer. |
CD274 |
| 54 |
33620088 |
10.1111/bjh.17362 |
2021 |
Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma. |
CD274 |
| 55 |
33655698 |
10.1002/cam4.3649 |
2021 |
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. |
CD274 |
| 56 |
33674274 |
10.1158/1078-0432.CCR-21-0133 |
2021 |
Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. |
CD274 |
| 57 |
33686666 |
10.1111/bjh.17366 |
2021 |
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. |
CD274 |
| 58 |
33691262 |
10.1016/j.ejca.2021.01.020 |
2021 |
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. |
CD274 |
| 59 |
33721375 |
10.1111/ejh.13621 |
2021 |
Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. |
CD274 |
| 60 |
33764958 |
10.12659/MSM.929431 |
2021 |
Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells. |
CD274 |
| 61 |
33807678 |
10.3390/jof7030186 |
2021 |
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. |
CD274 |
| 62 |
33847923 |
10.1007/s12094-021-02579-9 |
2021 |
Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs). |
CD274 |
| 63 |
33889438 |
10.1080/2162402X.2021.1907059 |
2021 |
VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma. |
CD274 |
| 64 |
33918793 |
10.3390/cancers13081801 |
2021 |
Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets. |
CD274 |
| 65 |
33941556 |
|
2021 |
PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation. |
CD274 |
| 66 |
33972504 |
10.1038/s41408-021-00477-5 |
2021 |
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. |
CD274 |
| 67 |
34021249 |
10.1038/s41375-021-01289-z |
2021 |
Thyroid MALT lymphoma: self-harm to gain potential T-cell help. |
CD274 |
| 68 |
34060602 |
10.1042/BSR20204186 |
2021 |
Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes. |
CD274 |
| 69 |
34077007 |
|
2021 |
Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings. |
CD274 |
| 70 |
34078046 |
10.3760/cma.j.cn112151-20201223-00953 |
2021 |
[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma]. |
CD274 |
| 71 |
34125179 |
10.1182/blood.2021011366 |
2021 |
Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations. |
CD274 |
| 72 |
34130989 |
10.1136/jitc-2021-002558 |
2021 |
Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. |
CD274 |
| 73 |
34153661 |
10.1016/j.intimp.2021.107870 |
2021 |
PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. |
CD274 |
| 74 |
34181355 |
10.31557/APJCP.2021.22.6.1943 |
2021 |
NFATc1 is Suppressed in Tumor Microenvironment of Hodgkin Lymphoma. |
CD274 |
| 75 |
34257603 |
10.3389/pore.2021.637745 |
2021 |
Case Report: A Case Report of a Histological Transformation of <i>ALK</i>-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib. |
CD274 |
| 76 |
34327781 |
10.1111/cas.15091 |
2021 |
Current progress and future perspectives of research on intravascular large B-cell lymphoma. |
CD274 |
| 77 |
34363798 |
10.1016/j.humpath.2021.07.011 |
2021 |
Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan. |
CD274 |
| 78 |
34405609 |
10.3760/cma.j.cn112151-20210110-00023 |
2021 |
[Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation]. |
CD274 |
| 79 |
34534136 |
10.1097/PAS.0000000000001809 |
2021 |
Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells. |
CD274 |
| 80 |
34543472 |
10.1002/hon.2926 |
2021 |
Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma. |
CD274 |
| 81 |
34558414 |
10.5152/balkanmedj.2021.20086 |
2021 |
Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma. |
CD274 |
| 82 |
34584457 |
10.2147/CMAR.S317319 |
2021 |
Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma. |
CD274 |
| 83 |
34600407 |
10.1016/j.lungcan.2021.09.011 |
2021 |
Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. |
CD274 |
| 84 |
34615710 |
10.1073/pnas.2105822118 |
2021 |
Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. |
CD274 |
| 85 |
34649362 |
10.1016/j.biopha.2021.112238 |
2021 |
An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers. |
CD274 |
| 86 |
34661162 |
10.1158/2643-3230.BCD-21-0044 |
2021 |
Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. |
CD274 |
| 87 |
34742294 |
10.1186/s13000-021-01163-7 |
2021 |
Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers. |
CD274 |
| 88 |
34955650 |
10.2147/IJGM.S341557 |
2021 |
Combined Identification of Novel Markers for Diagnosis and Prognostic of Classic Hodgkin Lymphoma. |
CD274 |
| 89 |
30225784 |
10.1007/s12253-018-0469-6 |
2020 |
The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay. |
CD274 |
| 90 |
31163235 |
10.1016/j.jaad.2019.05.077 |
2020 |
Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. |
CD274 |
| 91 |
31330525 |
10.1159/000500974 |
2020 |
Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance. |
CD274 |
| 92 |
31383967 |
10.1038/s41379-019-0336-3 |
2020 |
PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. |
CD274 |
| 93 |
31493237 |
10.1007/s00535-019-01616-3 |
2020 |
Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma. |
CD274 |
| 94 |
31532724 |
10.1200/JCO.19.01056 |
2020 |
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. |
CD274 |
| 95 |
31598903 |
10.1007/s12094-019-02218-4 |
2020 |
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. |
CD274 |
| 96 |
31653980 |
10.1038/s41379-019-0392-8 |
2020 |
Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. |
CD274 |
| 97 |
31699300 |
10.1016/j.pathol.2019.09.005 |
2020 |
Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. |
CD274 |
| 98 |
31709594 |
10.1002/cbf.3463 |
2020 |
Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape. |
CD274 |
| 99 |
31747139 |
10.1002/cam4.2670 |
2020 |
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses. |
CD274 |
| 100 |
31752573 |
10.1080/10428194.2019.1691200 |
2020 |
New murine models of aggressive lymphoma. |
CD274 |
Datasets
Models
